By Tiffany Williams –
BOSTON — A new clinical trial led by researchers from Mass General Brigham suggests that patients with small cell lung cancer (SCLC) and limited brain metastases can be effectively treated with targeted radiation, potentially avoiding the side effects of traditional whole brain radiation.
The results, published in the Journal of Clinical Oncology, stem from a phase 2, multi-center study involving 100 patients with 1 to 10 brain metastases. Researchers trialed stereotactic radiation — a highly focused form of radiation therapy — and found it offered positive outcomes that may support shifting away from the historical standard of whole brain radiation.
“Despite being the historical standard, whole brain radiation might not be necessary for all patients,” said first author Ayal Aizer, MD, MHS, director of Central Nervous System Radiation Oncology at Brigham and Women’s Hospital, a founding member of the Mass General Brigham healthcare system. “Our findings demonstrate that targeted, brain-directed radiation may be a viable treatment for patients with limited brain metastases from small cell lung cancer and potentially spare them from the side effects of whole brain radiation.”
Whole brain radiation treats the entire brain to eliminate tumor cells but can lead to long-term cognitive side effects. Stereotactic radiation, in contrast, targets only the tumor sites, helping preserve healthy brain tissue.
Between 2018 and 2023, the enrolled patients received stereotactic radiation with close follow-up monitoring. The study found that the one-year neurological death rate was 11%, notably lower than the historical rate of 17.5% seen in patients treated with whole brain radiation. Most patients in the study did not require whole brain radiation later on.
“These results support a shift toward more personalized, targeted treatment approaches that can help maintain quality of life while effectively managing brain metastases,” Aizer said. “By avoiding whole brain radiation in select patients, we may be able to improve quality of life and reduce cognitive side effects without compromising outcomes.”
The findings mark a potential step forward in the treatment of brain metastases for patients with SCLC, who until now have lacked dedicated studies evaluating the effectiveness of stereotactic radiation in their care.